BOULDER, Colo., March 23 /PRNewswire/ -- N30 Pharma (N30) today announced that Joseph Loscalzo, M.D., PhD., has joined the Board of Directors of the Company.
Dr. Loscalzo currently serves as Hersey Professor of the Theory and Practice of Medicine at Harvard, Physician-in-Chief at Brigham and Women’s Hospital, Editor-in-Chief of Circulation, and has recently joined the senior editorial Board of Harrison’s Principles of Internal Medicine. Dr. Loscalzo has longstanding research interests in cardiovascular medicine, nitric oxide and redox biology with over 500 scientific publications and authoring or editing of 24 books.
“I am pleased to join the Board of N30 at an exciting time for the company. N30 is developing compounds of substantial potential importance that offer a unique means for modulating endogenous NO in the cardiovascular and pulmonary systems, and I look forward to helping the Board in managing the future of the Company,” Dr. Loscalzo commented.
Dr. Loscalzo will also Chair the company’s Scientific Advisory Board. The N30 SAB will provide the company with world-class thinking on the key biological, biochemical, translational, and clinical issues associated with developing important new classes of therapeutics in cardiopulmonary medicine.
Dr. Charles Scoggin, CEO of N30, commented on the expansion of the Board. “We are thrilled that a world-class clinical and scientific mind like Dr. Loscalzo shares our excitement over the great clinical potential in N30 Pharma, and we will look forward to working closely with him as we move the company forward.”
About N30 Pharma
N30 Pharma is a cardiopulmonary medicine company focused on the modulation of endogenous Nitric Oxide bioavailability using targeted novel small molecule drugs. The company is headquartered in Boulder, Colorado and New York City, NY.
CONTACT: N30 Pharma, +1-720-945-7700, info@N30pharma.com
Web site: http://www.n30pharma.com/
